0 -0.00139664804469286 -0.0015363128491622 -0.0015363128491622 -0.0015363128491622 -0.0015363128491622 -0.0015363128491622 -0.0015363128491622
Sign Up Today X
Thanks for submitting the form.
Stockreport

Gilead Sciences, Inc. (GILD): A Bull Case Theory [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences, Inc.'s share was trading at $141.95 as of January 30th. GILD's trailing and forward P/E were 21.60 and 15.87 respectively according to Yahoo Finance. BlurryMe/Shutterstock.com Gilead Sciences (GILD), historically a leader in HIV and hepatitis C treatments, is now positioning oncology as its next growth engine through a strategy focused on licensing and targeted acquisitions rather than large-scale buyouts. The company's approach emphasizes “precision oncology,” matching therapies to patients whose tumors carry specific genetic vulnerabilities, which can enhance efficacy and justify premium pricing. A recent agreement with Repare Therapeutics exemplifies this strategy, expanding Gilead's pipeline in DNA-repair-targeted cancer therapies. If its existing oncology drug Trodelvy achieves projected growth and multiple licensed programs reach commercialization, analysts estimate that oncology could contribute several billion dollars in annual revenue by the latter half [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Gilead Sciences, Inc. (GILD): A Bull Case Theory [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences, Inc.'s share was trading at $141.95 as of January 30th. GILD's trailing and forward P/E were 21.60 and 15.87 respectively according to Yahoo Finance. BlurryMe/Shutterstock.com Gilead Sciences (GILD), historically a leader in HIV and hepatitis C treatments, is now positioning oncology as its next growth engine through a strategy focused on licensing and targeted acquisitions rather than large-scale buyouts. The company's approach emphasizes “precision oncology,” matching therapies to patients whose tumors carry specific genetic vulnerabilities, which can enhance efficacy and justify premium pricing. A recent agreement with Repare Therapeutics exemplifies this strategy, expanding Gilead's pipeline in DNA-repair-targeted cancer therapies. If its existing oncology drug Trodelvy achieves projected growth and multiple licensed programs reach commercialization, analysts estimate that oncology could contribute several billion dollars in annual revenue by the latter half [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS